AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 82 min read$SNDK

First Look: Sandisk Surges, Novartis Falls, WaFd-EverBank Merger

Novartis NOVN shares fell 9% after reporting three drug trial failures, impacting rivals Amgen AMGN and Eli Lilly LLY. Sandisk SNDK shares rose 12% ahead of S&P 100 inclusion. EverBank and WaFd WAFD agreed to a $3.9B reverse merger. Brent crude approached $100/barrel due to Strait of Hormuz tensions. Gold prices dropped over 2% on strong U.S. payroll data.

Original reporting
gurufocus.com
Published Sep 8, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 2:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$SNDK
Bullish
high confidence
Mentioned
$SNDK · $NVS · $WAFD · $ARM
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$SNDKBullishMed
01

Why it matters

Each headline provides a distinct catalyst that could move the respective stock.

02

Market read

The mix of earnings‑type news, a merger, and a product launch offers multiple short‑term trading ideas.

03

What to watch

Novartis may have pipeline assets that offset the trial setbacks in the longer term.

Relevance 7/10Novelty 7/10Timing: today

Background

The article aggregates several unrelated corporate updates released on September 8, 2026.

Company-level read

Ticker impact

$SNDKBullishHigh confidence
Context

Sandisk shares surged nearly 12% ahead of its inclusion in the S&P 100.

Expected impact

Short‑term upside as index funds add exposure.

Evidence & confidence

Inclusion typically triggers buying pressure from index‑tracking funds.

$NVSBearishHigh confidence
Context

Novartis stock fell 9% after reporting three drug‑trial failures in one week.

Expected impact

Further downside risk if pipeline concerns persist.

Evidence & confidence

Trial setbacks directly affect future revenue expectations.

$WAFDBullishMedium confidence
Context

WaFd announced a $3.9 billion reverse merger with EverBank.

Expected impact

Potential upside as market prices merger synergies.

Evidence & confidence

Reverse mergers can unlock value but execution risk remains.

$ARMBullishMedium confidence
Context

Arm unveiled next‑gen mobile and server chips, including the Mali G2‑Ultra GPU.

Expected impact

Likely modest rally on tech‑sector optimism.

Evidence & confidence

Product launches can lift sentiment but immediate revenue impact is limited.

Market effects

Sector

Memory, pharma, and digital banking sectors see heightened volatility.

Regional

U.S. markets react to the mixed news across technology and healthcare.

Global

Novartis trial failures may influence global biotech sentiment.

Counterpoint

What could challenge this read

Despite the rally, Sandisk could face valuation pressure if inclusion expectations fade.

Key entities

  • Company
    Sandisk

    Memory chip maker slated for S&P 100 inclusion.

  • Company
    Novartis

    Swiss pharma giant reporting trial failures.

  • Company
    WaFd Financial

    Regional bank entering a reverse merger with EverBank.

  • Company
    Arm Holdings

    Semiconductor designer launching new GPU and server chips.

Read at source← All news

Related articles

SEP 10
$NVSMedAI 8/10

The Most Promising New Cholesterol Drug Didn’t Work. Now What?

Novartis' pelacarsen, a cholesterol drug targeting lipoprotein(a), failed to reduce cardiovascular events in a clinical trial. The result questions whether lipoprotein(a) is a cause or marker of risk. Full data is pending, and other similar drugs are in trials. The company had high hopes for the drug, which had shown significant reductions in lipoprotein(a) levels.

menshealth.com2 min
SEP 10
$NVSLow

Muscular dystrophy AOC drug from Novartis fails clinical trial

Novartis' AOC drug delpacibart etedesiran failed to meet primary endpoints in a Phase III trial for myotonic dystrophy type 1. The drug did not show significant improvement over placebo. Novartis shares have declined 14% following this and other recent clinical trial setbacks. The company maintains a 5-6% five-year sales growth target, according to a public statement.

bioxconomy.com2 min
SEP 10
$SNDKHighAI 8/10

Can SanDisk Stock Keep Climbing When It Cannot Make Enough To Sell?

SanDisk (SNDK) reported $20.2B revenue for fiscal 2026, with stock up 2,700% in 12 months. Supply growth is limited, with demand outpacing supply. Pricing and data center revenue growth drive performance. Fiscal Q1 2027 guidance: $10.3B-$10.8B revenue, 83%-85% gross margin. Data center revenue rose to 33% in Q4 2026.

yahoo.com2 min
SEP 10
$NVDAMed

Piper Sandler lists 5 chip stocks to buy

Piper Sandler initiated coverage of five AI chip stocks, rating them Overweight. Nvidia (NVDA) was given a $300 price target, with an 80% market share in AI compute. Broadcom (AVGO) was started at $460, with a 75% share in custom ASIC chips. AMD (AMD) was initiated at $600, with a 65% earnings growth forecast. Marvell (MRVL) and Arm Holdings (ARM) were also covered, with price targets of $270 and $320, respectively.

investing.com2 min
SEP 10
$NVSMed

HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review

HSBC adjusted ratings for biopharma stocks, citing high multiples and the need for stock-specific catalysts. Novartis was upgraded to Hold with a target price of 110 CHF, while Amgen was downgraded to Hold with a target of $425. AbbVie and Bayer were kept as Buy with raised targets. The changes reflect expectations for upcoming clinical trials and legal outcomes.

investing.com2 min
SEP 10
$ARMMed

Arm Expands Battle Lines Deep Into the x86 Stronghold: Disruptive Competition Reshaping the Global CPU Market

Arm updated its mobile, cloud, and AI product lines, expanding into the cloud segment with the Neoverse CSS N4 and AGI CPU. The company reported Q1 2027 revenue of $1.289B, up 22.4% YoY, with licensing and royalty revenues at $574M and $715M respectively. Arm is extending its business model to offer more complete products, aiming to capture new growth opportunities in AI. Chinese companies like Volcano Engine and Lenovo are adopting Arm's AGI CPU for AI services and infrastructure.

eu.36kr.com2 min